The atypical antipsychotic drug Invega may be associated with gynecomastia, or male breast growth. Men and boys who developed this embarrassing condition while using the medication may be entitled to financial compensation from Johnson & Johnson and Janssen Pharmaceuticals. These companies also market a related antipsychotic called Risperdal, which is already named in thousands of gynecomastia lawsuits. Filing a similar legal claim could be an option for those allegedly suffering from Invega-related male breast development.
The nationwide law firm of Bernstein Liebhard LLP is offering free legal reviews to individuals interested in pursuing an Invega lawsuit for gynecomastia. To learn more, please call .
Invokana contains an active metabolite of risperidone, the primary ingredient in Risperdal. Studies have found that exposure to risperidone is often associated with elevated levels of a hormone called prolactin. While other antipsychotics can also cause an overproduction of prolactin, risperidone is associated with higher levels than other drugs in this class.
Prolactin plays a key role in breast development and lactation in women. Higher-than normal levels in men and boys have also been tied to gynecomastia. The Invega label notes that the medication can have the same elevating effect on prolactin that has been observed in patients treated with risperidone.
Gynecomastia may affect one or both breasts and can develop in newborn infants, during puberty or in older men, usually as a result of normal hormonal changes. Excessive male breast development can also be a side effect of certain medications, including steroids and antipsychotics.
Symptoms associated with gynecomastia include:
Treatment for Invega-induced gynecomastia may include:
Thousands of Risperdal lawsuits have been filed in U.S. courts on behalf of men and boys who allegedly experienced excessive breast growth due to their use of that medication. One of the largest litigations is currently underway in Pennsylvania’s Philadelphia Court of Common Pleas, where five gynecomastia trials had been convened as of July 2016. In all of those cases, the juries determined that Johnson & Johnson and its Janssen Pharmaceuticals unit had failed to provide patients and doctors with adequate safety warnings. Four of the plaintiffs were awarded significant compensatory damages, ranging from $500,000 to $70 million.
Alleged victims of Invega-related gynecomastia may also be entitled to compensation for medical bills, pain and suffering, psychological distress and more. To discuss filing an Invega lawsuit for male breast growth, please contact Bernstein Liebhard LLP today at .